Monday 13 July 2020 \

 

Russia developed a drug against COVID-19

Moscow, June 1, 2020

Russia has developed a promising new treatment for the coronavirus COVID-19. The Russian Direct Investment Fund (RDIF), the country’s sovereign wealth fund, is set to unveil the new drug, Avifavir, at a virtual press conference in Moscow today on Monday.

RDIF said that the drug, which “has shown high efficacy in treating patients with coronavirus during clinical trials,” had received a registration certificate from the Russian health ministry.

Avifavir, which disrupts the reproduction mechanisms of coronavirus, is the first Russian direct antiviral drug that has proven effective in clinical trials. The drug has been well studied, since it has been used in Japan since 2014 against severe forms of influenza, RDIF said.

Dmitriev added: “Afivavir is not only the first antiviral drug registered against coronavirus in Russia, but it is also perhaps the most promising anti-COVID-19 drug in the world. It was developed and tested in clinical trials in Russia in an unprecedentedly short period of time enabling Afivavir to become the first registered drug based on Favipiravir in the world.” Favipiravir is a drug that has proven effective in the treatment of infected patients in China and in clinical trials in Russia. Preparations are currently underway for the mass production of the drug.

Avifavir proved to be highly effective during the clinical trials involving I.M. Sechenov First Moscow State Medical University, Lomonosov Moscow State University and other medical and academic institutions, it added.

 

We recommend

Social Networks